Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.68 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602725 | 0.84 | S1PR1 (0.81) | S1PR1S1PR3MAOB | |
| SCHEMBL3812511 | 0.82 | S1PR1 (0.69) | S1PR1S1PR3ACHEHRH3 | |
| SCHEMBL1601177 | 0.81 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL12730038 | 0.81 | S1PR1 (0.69) | S1PR1S1PR3ACHECHKA | |
| SCHEMBL12729899 | 0.78 | S1PR1 (0.72) | S1PR1S1PR3ACHECHKANPC1 | |
| SCHEMBL12729542 | 0.77 | S1PR1 (0.72) | S1PR1S1PR3ACHEMAOBNPC1 | |
| SCHEMBL1601212 | 0.76 | S1PR1 (0.56) | S1PR1S1PR3MAOBMAOA | |
| SCHEMBL20013868 | 0.72 | HRH3 (0.65) | HRH4HRH3 | |
| SCHEMBL1602626 | 0.71 | S1PR1 (0.83) | S1PR1S1PR3 | |
| SCHEMBL30596572 | 0.70 | HRH3 (0.69) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010522162-A | — | — | 2010-07-01 | — | — | JP | claimed |
| EP-2121648-A2 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885ACHE 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.